Tyrosine kinase inhibitors that target RET, such as vandetanib and cabozantinib, have showed promise in clinical studies, while particular inhibitors for RET/PTC-positive thyroid tumors are currently being investigated (54). The gene discussed is RET; the disease is thyroid tumor.